Stellar Biotechnologies Appoints Tessie Che, Ph.D. to Board of Directors
25 Settembre 2013 - 3:05PM
Marketwired
Stellar Biotechnologies, Inc. ("Stellar" or "the
Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), is very pleased
to announce the appointment of Tessie Mary Che, Ph.D. to the
Company's Board of Directors.
Dr. Tessie Che is currently Chair of the Board of Directors of
Amaran Biotechnology, Inc., a private biotech company based in
Taiwan. Stellar's recent US$12 Million Private Placement included a
$5 Million investment by Amaran Biotechnology.
"Dr. Che brings to Stellar extensive experience pertinent to our
key corporate goals at this high-growth stage," said Frank Oakes,
Stellar President and CEO. "She co-founded and successfully led a
biopharmaceutical firm from development to commercialization of a
new drug product to treat Clostridium difficile. In addition, Dr.
Che has extensive scientific and operations acumen, as well as
strategic ability transforming research programs and pipelines into
high-value business assets."
"It is my pleasure to join Stellar's Board of Directors," said
Tessie Mary Che, Ph.D. "Stellar's proprietary strength in KLH
protein manufacturing and its vision to target the active
immunotherapy market makes this an impressive company with very
high commercial potential."
Dr. Che co-founded Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR)
in 1998 and served over ten years as Optimer's Chief Operating
Officer and Senior Vice President of Corporate Affairs. During the
process development years of Optimer's flagship drug, DIFICID®, Dr.
Che built and led the company's Chemistry, Manufacturing and
Quality Control (CMC) teams through the successful and
cost-effective registration and commercialization of DIFICID® in
the United States, Canada and Europe in 2011.
Prior to Optimer, Dr. Che's industrial experience included 20
years in research, management and operations at large companies
including Exxon Mobil Corporation, Aventis Pharmaceuticals, Inc.,
and EniChem S.p.A. She also served as Vice President, Operations of
M and D Precision Science Group, Inc. in 1988 and co-founded
Cinogen Pharmaceuticals, Inc. (China) serving as Vice President
from 1994 to 1996. Cinogen later became a wholly-owned subsidiary
of Pharmanex, Inc., where Dr. Che served as Sr. Director of Quality
Assurance and Sourcing.
Dr. Che holds bachelors' degrees in chemistry from Illinois
State University and Fu-Jen Catholic University (Taiwan), a Ph.D.
in physical-inorganic chemistry from Brandeis University, and did
post-doctoral work at Columbia University. She has authored
numerous scientific publications and holds over twenty U.S. patents
in material synthesis and applications.
About Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. (TSX
VENTURE: KLH) (OTCQB: SBOTF) is the world leader in sustainable
manufacture of Keyhole Limpet Hemocyanin (KLH), an important
immune-stimulating protein used in wide-ranging therapeutic and
diagnostic markets. KLH is both an active pharmaceutical ingredient
(API) in many new immunotherapies (targeting cancer, infectious
diseases, and immune disorders) as well as a finished product for
measuring immune status. Stellar Biotechnologies is unique in its
proprietary methods, facilities, and KLH technology. We are
committed to meeting the growing demand for commercial-scale
supplies of GMP grade KLH, ensuring environmentally sound KLH
production, and developing KLH-based active immunotherapies.
To receive regular updates, enter email at
http://stellarbiotechnologies.com/contact/
Visit www.StellarBiotech.com and the KLH
knowledge base www.KLHSite.com.
Forward Looking Statements There can be no
assurance that forward-looking statements will prove to be
accurate, as actual results and future events could differ
materially from those anticipated in such statements. Readers
should not place undue reliance on such statements. Except in
accordance with applicable securities laws, the Company expressly
disclaims any obligation to update any forward-looking statements
or forward-looking statements that are incorporated by reference
herein. This news release does not constitute an offer to sell, or
a solicitation of an offer to buy any of the Company's securities
set out herein in the United States, or to, or for the benefit or
account of, a U.S. Person or person in the United States. Neither
TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of these
releases.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contacts: Frank Oakes President and CEO Phone +1 (805)
488-2800 InvestorRelations@stellarbiotech.com Investor
Relations: MZ Group Mark A. McPartland Senior Vice President
Phone: +1 (212) 301-7130 markmcp@mzgroup.us Web: www.mzgroup.us
Grafico Azioni Serve Robotics (QB) (USOTC:SBOT)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Serve Robotics (QB) (USOTC:SBOT)
Storico
Da Giu 2023 a Giu 2024